Ligand‐Engineered Cu 13 Nanoclusters Direct Distinct Programmed Cell Death Pathways for Tumor‐Selective Therapy
Small · 2026-08 · 22 (47)
DOI: 10.1002/smll.74318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 26.06.2026. Verfasst von Qian Han und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Basic Medical Sciences, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Copper, Apoptosis, Neoplasms. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Hunan Provincial Key Research and Development Plan Project, Hunan Provincial Natural Science Foundation.
Abstract (Originalsprache)
Programmed cell death (PCD) pathways such as apoptosis and pyroptosis play a pivotal role in cancer therapy, yet achieving precise and selective activation of these pathways using nanomaterials remains a major challenge. Here, we report the synthesis of two quasi‐structurally isomeric 13‐nuclear copper nanoclusters that share an identical Cu 13 core but differ in peripheral ligands, i.e. Cu 13 ‐OH and Cu 13 ‐F . These ligand‐engineered nanoclusters elicit different cellular localization and reactive oxygen species (ROS) generation profiles, and thereby selectively activate distinct PCD mechanisms for efficient and low‐toxicity tumor therapy. Specifically, Cu 13 ‐OH anchors onto cell membranes and forms nano‐spike protrusions that disrupt cytoskeletal organization and suppress PI3K‐AKT signalling, leading to caspase‐dependent apoptosis with a concentration‐threshold response. In contrast, Cu 13 ‐F shows enhanced cellular uptake/internalization and stronger ROS‐generation capability, which may be associated with fluorination‐modulated copper redox behavior, thereby activating Caspase‐4/Gsdmd‐mediated pyroptosis. Both in vitro and in vivo studies conclude potent tumor‐selective inhibition, particularly that Cu 13 ‐F exhibits exceptional efficacy at low‐doses due to its enhanced membrane permeation and robust ROS generation. These findings confirm ligand engineering as a versatile strategy for precise spatial modulation of PCD pathways, offering a new paradigm for feasible design of tumor‐selective nanomedicines through subtle atomic‐level modifications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, College of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
- College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan, China.
- Furong Laboratory, Changsha, Hunan, China.
- National Engineering Research Center of Personalized Diagnostic and Therapeutic, Changsha, Hunan, China.
ORCID-Profile: Chao Liu, Zhuxin Dong
Förderung
- National Natural Science Foundation of China
- Hunan Provincial Key Research and Development Plan Project
- Hunan Provincial Natural Science Foundation
- Natural Science Foundation of Hunan Province
Zitieren
APA
Han, Q., Chen, X., Peng, X., Zhang, Z., He, Y., Zhou, Z., Liu, C., & Dong, Z. (2026). Ligand‐Engineered Cu 13 Nanoclusters Direct Distinct Programmed Cell Death Pathways for Tumor‐Selective Therapy. Small, 22(47). https://doi.org/10.1002/smll.74318
Vancouver
Han Q, Chen X, Peng X, Zhang Z, He Y, Zhou Z, et al. Ligand‐Engineered Cu 13 Nanoclusters Direct Distinct Programmed Cell Death Pathways for Tumor‐Selective Therapy. Small. 2026;22(47). doi:10.1002/smll.74318
BibTeX
@article{Han2026,
author = {Han, Qian and Chen, Xinyu and Peng, Xuan and Zhang, Ziyan and He, Yilong and Zhou, Zheyuan and Liu, Chao and Dong, Zhuxin},
title = {Ligand‐Engineered Cu 13 Nanoclusters Direct Distinct Programmed Cell Death Pathways for Tumor‐Selective Therapy},
journal = {Small},
year = {2026},
volume = {22},
number = {47},
doi = {10.1002/smll.74318}
}
EUVIMED